/BHVN
BHVN Stock - Biohaven Ltd.
Healthcare|BiotechnologyNYSE
$10.85-2.47%
$0.28 (-2.47%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+107.4%upside
Target: $22.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BHVN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$10.74 – $10.96
TARGET (TP)$22.50
STOP LOSS$9.98
RISK/REWARD1:13.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.59
52W High$44.28
52W Low$7.48
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-885,111,000 | $-436,051,000 | $-567,932,000 | $-218,900,000 | $-114,506,000 |
| Net Income | $-846,422,000 | $-408,168,000 | $-570,279,000 | $-213,796,000 | $-118,668,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-9.28 | $-5.73 | $-12.75 | $-5.97 | $-3.31 |
Company Overview
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Visit WebsiteRating Distribution
Strong Buy
1
6%
Buy / Outperform
10
63%
Hold / Neutral
5
31%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
11 Bullish5 Neutral/Bearish
Price Targets
$52
Average Target
↑ 379.9% Upside
Now
$9
Low
$52
Average
$150
High
Based on 23 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | H.C. Wainwright | Downgrade | Neutral | $11 |
| November 26th 2025 | UBS | Downgrade | Neutral | $11 |
| November 6th 2025 | Bernstein | Downgrade | Market Perform | $9 |
| November 5th 2025 | BofA Securities | Downgrade | Neutral | $10 |
| September 17th 2025 | Citigroup | Initiation | Buy | $28 |
| September 3rd 2025 | Raymond James | Initiation | Strong Buy | $75 |
| May 19th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $21 |
| February 11th 2025 | Deutsche Bank | Initiation | Buy | $65 |
| September 16th 2024 | Jefferies | Initiation | Buy | $57 |
| September 4th 2024 | Bernstein | Initiation | Outperform | $55 |
| July 24th 2024 | Morgan Stanley | Initiation | Overweight | $58 |
| February 16th 2024 | RBC Capital Mkts | Initiation | Outperform | $62 |
| February 6th 2024 | UBS | Initiation | Buy | $59 |
| December 22nd 2023 | H.C. Wainwright | Initiation | Buy | $50 |
| December 8th 2023 | Robert W. Baird | Initiation | Outperform | $58 |
Earnings History & Surprises
BHVNBeat Rate
16%
Last 19 quarters
Avg Surprise
-31.9%
EPS vs Estimate
Beats / Misses
3/14
2 met exactly
Latest EPS
$-1.64
Q4 2025
EPS Surprise History
Q1 24
-28.4%
$-1.81vs$-1.41
Q2 24
-46.7%
$-2.20vs$-1.50
Q3 24
-111.6%
$-3.64vs$-1.72
Q4 24
0.0%
$-1.70vs$-1.70
Q1 25
-18.6%
$-1.85vs$-1.56
Q2 25
-29.9%
$-2.17vs$-1.67
Q3 25
0.0%
$-1.94vs$-1.94
Q4 25
+14.1%
$-1.64vs$-1.91
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 2, 2026 | $-1.32 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-1.91 | $-1.64 | +14.1% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-1.94 | $-1.94 | 0.0% | = MET |
Q2 2025 | May 12, 2025 | $-1.67 | $-2.17 | -29.9% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-1.56 | $-1.85 | -18.6% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-1.70 | $-1.70 | 0.0% | = MET |
Q3 2024 | Aug 8, 2024 | $-1.72 | $-3.64 | -111.6% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-1.50 | $-2.20 | -46.7% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-1.41 | $-1.81 | -28.4% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-1.33 | $-1.50 | -12.8% | ✗ MISS |
Q3 2023 | Jul 31, 2023 | $-1.24 | $-1.32 | -6.5% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-1.39 | $-1.03 | +25.9% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-1.24 | $-3.32 | -167.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-2.53 | $-1.75 | +30.8% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $-2.79 | $-6.21 | -122.6% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-2.52 | $-2.97 | -17.9% | ✗ MISS |
Q1 2022 | Feb 25, 2022 | $-2.07 | $-3.01 | -45.4% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-2.44 | $-2.63 | -7.8% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-2.77 | $-3.23 | -16.6% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-2.92 | $-4.21 | -44.2% | ✗ MISS |
Latest News
Biohaven jumps on early-stage data for antibody drug conjugate combo
📈 PositiveSeeking Alpha•Dec 11, 2025, 07:56 PM
Biohaven Presents Phase 1 Data For Next-Generation Trop2 ADC BHV-1510 Plus Cemiplimab At 2025 ESMO Immuno-Oncology Congress Showing 60% ORR In NSCLC, 100% In Endometrial Cancer And 50% In Urothelial Cancer With Differentiated Safety Profile
📈 PositiveBenzinga•Dec 11, 2025, 12:11 PM
HC Wainwright & Co. Downgrades Biohaven to Neutral, Lowers Price Target to $11
📉 NegativeBenzinga•Dec 3, 2025, 12:11 PM
UBS Downgrades Biohaven to Neutral, Lowers Price Target to $11
📉 NegativeBenzinga•Nov 26, 2025, 02:42 PM•Also:
JP Morgan Maintains Overweight on Biohaven, Lowers Price Target to $15
➖ NeutralBenzinga•Nov 20, 2025, 06:42 PM
Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $26
➖ NeutralBenzinga•Nov 18, 2025, 06:16 PM
BTIG Reiterates Buy on Biohaven, Maintains $16 Price Target
📈 PositiveBenzinga•Nov 18, 2025, 11:46 AM
Citigroup Maintains Buy on Biohaven, Lowers Price Target to $14
➖ NeutralBenzinga•Nov 13, 2025, 07:43 PM•Also:
Biohaven announces pricing of $175M public offering of common shares
➖ NeutralSeeking Alpha•Nov 12, 2025, 12:21 PM
Biohaven Prices ~$175M Offering Of 23.3M Common Shares At $7.50/Share
➖ NeutralBenzinga•Nov 12, 2025, 12:16 PM•Also:
BHVN stock has given up its prior loss. Biohaven shares were trading lower after the company announced a $150 million offering.
➖ NeutralBenzinga•Nov 11, 2025, 09:42 PM
Biohaven shares are trading lower after the company announced a $150 million offering.
📉 NegativeBenzinga•Nov 11, 2025, 09:12 PM
Biohaven Announces $150M Common Stock Offering
➖ NeutralBenzinga•Nov 11, 2025, 09:06 PM
Biohaven Q3 Adj. EPS $(1.47) Beats $(1.73) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 12:01 PM
Bernstein Downgrades Biohaven to Market Perform, Lowers Price Target to $9
📉 NegativeBenzinga•Nov 6, 2025, 05:57 PM
RBC Capital Maintains Sector Perform on Biohaven, Lowers Price Target to $9
➖ NeutralBenzinga•Nov 6, 2025, 03:38 PM
BTIG Maintains Buy on Biohaven, Lowers Price Target to $16
➖ NeutralBenzinga•Nov 6, 2025, 09:52 AM
William Blair Downgrades Biohaven to Market Perform
📉 NegativeBenzinga•Nov 5, 2025, 11:52 PM
TD Cowen Maintains Buy on Biohaven, Lowers Price Target to $15
📈 PositiveBenzinga•Nov 5, 2025, 06:33 PM
Biohaven shares are trading lower. The company announced it received a Complete Response Letter from the FDA for the New Drug Application seeking approval of VYGLXIA for the treatment of spinocerebellar ataxia.
📉 NegativeBenzinga•Nov 5, 2025, 02:10 PM
Frequently Asked Questions about BHVN
What is BHVN's current stock price?
Biohaven Ltd. (BHVN) is currently trading at $10.85 per share. The stock has moved -2.47% today.
What is the analyst price target for BHVN?
The average analyst price target for BHVN is $22.50, based on 1 analyst.
What sector is Biohaven Ltd. in?
Biohaven Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is BHVN's market cap?
Biohaven Ltd. has a market capitalization of $1.15 billion, making it a small-cap company.
Does BHVN pay dividends?
No, Biohaven Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
IMCR
Immunocore Holdings plc
$36.01
Mkt Cap: $1.8B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
XERS
Xeris Biopharma Holdings, Inc.
$7.34
Mkt Cap: $1.2B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
Explore stocks similar to BHVN for comparison